New-generation interstitial PDT
IDOSE® for real-time adjustment of dosimetry plan
SpectraCure AB is commercialising its unique Photodynamic Therapy (PDT) system with IDOSE®* for interstitial PDT using real-time dosimetry. The technology behind this new-generation PDT is based on research carried out by Professor Sune Svanberg and colleagues at the Atomic Physics Division, Lund Technical University and the Lund University Medical Laser Centre.
The SpectraCure PDT System with IDOSE® has the potential to be used on a broad range of tumors such as pancreatic cancer, cholangiocarcinoma, cancer in the liver, as well as prostate cancer.
SpectraCure is about to conduct several studies on different indications such as recurrent prostate cancer and cancer of the pancreas.
The SpectraCure PDT System with IDOSE® has the potential to be used on a broad range of tumors such as pancreatic cancer, cholangiocarcinoma, cancer in the liver, as well as prostate cancer.
SpectraCure is about to conduct several studies on different indications such as recurrent prostate cancer and cancer of the pancreas.
* Interactive Dosimetery by Sequential Evaluation
SpectraCure has developed IDOSE®, an innovative and dedicated software for interstitial PDT. IDOSE® enables real-time, patient-specific and optimised interstitial PDT. It allows pretreatment planning including optimisation of optical fibre position and light dose calculation from each individual optical fibre. During PDT, IDOSE® also performs real-time adjustments of treatment-related parameters.
The SpectraCure PDT System with IDOSE® offers application flexibility and can be adapted to both different photosensitisers and different modalities.
The SpectraCure PDT System with IDOSE® offers application flexibility and can be adapted to both different photosensitisers and different modalities.
Advancing cancer treatment with IDOSE®
